Johnson & Johnson: XARELTO Helps Protect Pediatric Patients From Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
July 08, 2019
July 08, 2019
RARITAN, New Jersey, July 8 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- EINSTEIN-Jr Is The Largest Pediatric Trial Conducted For The Treatment of Venous Thromboembolism And The First to Evaluate a Direct Oral Anticoagulant in This Population
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, s . . .
* * *
- EINSTEIN-Jr Is The Largest Pediatric Trial Conducted For The Treatment of Venous Thromboembolism And The First to Evaluate a Direct Oral Anticoagulant in This Population
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, s . . .